Risk of Night Terrors with Montelukast Use
Montelukast carries a significant risk of nightmares and sleep disturbances in both children and adults, with the FDA issuing a boxed warning for neuropsychiatric events including "dream abnormalities" and "somnambulism" (sleepwalking), though the evidence does not clearly establish a dose-response relationship. 1
FDA-Mandated Warnings on Sleep-Related Neuropsychiatric Events
The FDA label explicitly lists "dream abnormalities" and "somnambulism" among serious neuropsychiatric events reported with montelukast use 1. These events:
- Occur in adults, adolescents, and pediatric patients
- Happen with or without prior psychiatric history
- Appear mostly during treatment but can persist after discontinuation
- Have led the FDA to recommend reserving montelukast for allergic rhinitis patients with inadequate response to alternatives
The FDA does not specify dose-related risk patterns, and standard dosing (10 mg adults, 5 mg children 6-14 years, 4 mg children 2-5 years) is not stratified by neuropsychiatric risk 1.
Quantified Risk from Pharmacovigilance Data
Children Are Disproportionately Affected
The most comprehensive characterization found 1,118 nightmare reports in VigiBase, with critical findings 2:
- Two-thirds of reports involved children, with peak incidence in ages 5-10 years
- Half of all nightmare reports were classified as serious
- Many cases described severe impact on daily functioning
- Nightmares typically resolved after discontinuation, though some persisted for extended periods
A tertiary center study of 385 children found 3:
- 15.1% experienced sleep disturbances (5.5% sleep difficulties, 4.4% sleep interruption, 1.82% nightmares specifically)
- Highest prevalence in children aged 4-9 years (52.8%)
- 0.6% of families stopped the drug specifically due to nightmares
Adults Also Experience Significant Risk
Multiple pharmacovigilance databases confirm nightmares are "often reported" in adults 4. A systematic review identified sleep disorders as consistently associated with montelukast in older adults 5.
No Clear Dose-Response Relationship Established
The available evidence does not demonstrate a dose-dependent relationship for nightmares or sleep disturbances 1, 2, 4, 3. The FDA label uses standard age-based dosing without neuropsychiatric risk stratification. However, one study found that prolonged duration beyond 63 days (not higher doses) increased neuropsychiatric risks in older children 6.
Critical Clinical Implications
When to Avoid Montelukast
Given the FDA's risk-benefit guidance 1:
- Do not use for mild allergic rhinitis adequately controlled by antihistamines or nasal corticosteroids
- Exercise extreme caution in children ages 4-10 years, where nightmare risk peaks 2, 3
- Consider alternative therapies first, particularly in patients with pre-existing sleep disorders
Monitoring Protocol
The FDA mandates specific counseling 1:
- Warn patients/caregivers upfront about neuropsychiatric risks including nightmares
- Instruct immediate discontinuation if nightmares or behavioral changes occur
- Continue monitoring after discontinuation since symptoms can persist
- Do not restart if neuropsychiatric events occurred
Common Pitfall to Avoid
The most recent large Swedish cohort study 7 found no increased neuropsychiatric risk compared to LABAs, but this study used composite outcomes and may have missed nightmare-specific signals. Do not dismiss individual patient reports of nightmares based on negative population studies—the FDA boxed warning is based on compelling post-marketing surveillance showing real clinical impact 1, 2.
Mechanistic Considerations
Montelukast distributes into the brain in animal studies 1, but mechanisms remain poorly understood. The lack of dose-response relationship suggests idiosyncratic rather than dose-dependent toxicity, making individual susceptibility unpredictable.